Department of Ophthalmology, Queen's University, Kingston, Ontario, Canada.
Ocul Immunol Inflamm. 2022 May 19;30(4):1005-1008. doi: 10.1080/09273948.2020.1841802. Epub 2021 Feb 4.
We describe a case vision-threatening sclerouveitis as a probable adverse drug reaction to ibrutinib.
Case report.
Ibrutinib is an inhibitor of Bruton's kinase which has shown success in the treatment of hematological malignancies such as chronic lymphocytic leukemia. Despite being generally well tolerated, recent studies have implicated ibrutinib in several adverse events affecting organs such as the heart, intestines, and the eyes. We present the case of a patient who developed severe sclerouveitis after approximately one year of ibrutinib therapy, and suggest this is a probable adverse drug reaction associated with ibrutinib in accordance with the Naranjo algorithm, highlighting the importance of prompt management of ocular symptoms in these patients.
我们描述了一例可能由伊布替尼引起的威胁视力的巩膜炎病例。
病例报告。
伊布替尼是布鲁顿酪氨酸激酶抑制剂，已被证明在治疗慢性淋巴细胞白血病等血液系统恶性肿瘤方面取得了成功。尽管总体耐受性良好，但最近的研究表明，伊布替尼与一些影响心脏、肠道和眼睛等器官的不良事件有关。我们报告了一例患者在接受伊布替尼治疗约一年后出现严重的巩膜炎，根据 Naranjo 算法，我们认为这是一种可能与伊布替尼相关的药物不良反应，强调了及时管理这些患者眼部症状的重要性。
